A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Exclusion Criteria

• •Must not have received prior treatment with another anti-IGF-1R therapy
• •Must not have received systemic corticosteroids for any condition, including TED, or selenium within 2 weeks prior to first dose.
• •Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED, within 12 weeks prior to first dose
• •Must not have received an investigational agent/device for any condition, including TED, within 8 weeks or longer (depending on the type of agent/device) prior to first dose
• •Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
• •Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
• •Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results
• •Must not have abnormal hearing test before first dose or history of ear conditions considered significant by study doctor
• •Must not have a history of inflammatory bowel disease
• •Female TED participants must not be pregnant or breastfeeding